Brandon A Mahal1, Yu-Wei Chen2, Roshan V Sethi1, Oscar A Padilla3, David D Yang4, Janice Chavez5, Vinayak Muralidhar1, Jim C Hu6, Felix Y Feng7, Karen E Hoffman8, Neil E Martin9, Daniel E Spratt10, James B Yu11, Peter F Orio9, Paul L Nguyen9. 1. Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts. 2. Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio. 3. Tufts University School of Medicine, Boston, Massachusetts. 4. Harvard Medical School, Boston, Massachusetts. 5. Department of Social Work, Brigham and Women's Hospital, Boston, Massachusetts. 6. Department of Urology, Weill Cornell Medicine, New York, New York. 7. Department of Radiation Oncology, University of California at San Francisco, San Francisco, California. 8. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 9. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts. 10. Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, Michigan. 11. Department of Therapeutic Radiology/Radiation Oncology, Yale University, New Haven, Connecticut.
Abstract
BACKGROUND: Definitive stereotactic body radiotherapy (SBRT) represents an emerging and debated treatment option for patients with prostate cancer, with potential economic savings and reports of short-term efficacy since 2006. The current study sought to define national trends in definitive prostate SBRT use and determine whether patterns vary by travel distance for treatment. METHODS: The National Cancer Data Base identified 181,544 men with localized prostate cancer who were treated with definitive external beam radiotherapy from 2004 through 2012. Joinpoint regression analyzed definitive prostate SBRT trends over time, whereas multivariable logistic regression defined the odds for its receipt by travel distance for treatment. RESULTS: Definitive prostate SBRT use increased from 1.8% in 2004 to 5.9% in 2012 (P for trend <.0001), with a joinpoint for increased use noted in 2006 (P<.0001). Higher SBRT use was found to be associated with longer travel distance for treatment, younger age, white race, more affluent zip code of residence, academic treatment center, favorable disease characteristics, and fewer comorbidities (all P<.0001). Compared with travel distances <25 miles for treatment, travel distances of 25 to 50 miles and >50 miles were associated with increasing adjusted odds of receipt of definitive prostate SBRT (1.63 [95% confidence interval, 1.51-1.76] and 2.35 [95% confidence interval, 2.14-2.57], respectively; both P < .0001). CONCLUSIONS: Definitive prostate SBRT use increased more than 3-fold since 2004, with a significant increase in use coinciding with early reports of short-term efficacy. Long-distance travel for treatment was associated with greater than twice the odds of receipt of definitive prostate SBRT compared with short-distance travel, suggesting that treatment decisions with unknown long-term clinical implications may be strongly driven by sociodemographic factors. Cancer 2018;124:1141-9.
BACKGROUND: Definitive stereotactic body radiotherapy (SBRT) represents an emerging and debated treatment option for patients with prostate cancer, with potential economic savings and reports of short-term efficacy since 2006. The current study sought to define national trends in definitive prostate SBRT use and determine whether patterns vary by travel distance for treatment. METHODS: The National Cancer Data Base identified 181,544 men with localized prostate cancer who were treated with definitive external beam radiotherapy from 2004 through 2012. Joinpoint regression analyzed definitive prostate SBRT trends over time, whereas multivariable logistic regression defined the odds for its receipt by travel distance for treatment. RESULTS: Definitive prostate SBRT use increased from 1.8% in 2004 to 5.9% in 2012 (P for trend <.0001), with a joinpoint for increased use noted in 2006 (P<.0001). Higher SBRT use was found to be associated with longer travel distance for treatment, younger age, white race, more affluent zip code of residence, academic treatment center, favorable disease characteristics, and fewer comorbidities (all P<.0001). Compared with travel distances <25 miles for treatment, travel distances of 25 to 50 miles and >50 miles were associated with increasing adjusted odds of receipt of definitive prostate SBRT (1.63 [95% confidence interval, 1.51-1.76] and 2.35 [95% confidence interval, 2.14-2.57], respectively; both P < .0001). CONCLUSIONS: Definitive prostate SBRT use increased more than 3-fold since 2004, with a significant increase in use coinciding with early reports of short-term efficacy. Long-distance travel for treatment was associated with greater than twice the odds of receipt of definitive prostate SBRT compared with short-distance travel, suggesting that treatment decisions with unknown long-term clinical implications may be strongly driven by sociodemographic factors. Cancer 2018;124:1141-9.
Authors: Evan M Graboyes; Mark A Ellis; Hong Li; John M Kaczmar; Anand K Sharma; Eric J Lentsch; Terry A Day; Chanita Hughes Halbert Journal: Cancer Date: 2018-06-22 Impact factor: 6.860
Authors: Chad Tang; Xiudong Lei; Grace L Smith; Hubert Y Pan; Karen E Hoffman; Rachit Kumar; Brian F Chapin; Ya-Chen Tina Shih; Steven J Frank; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2020-12-13 Impact factor: 7.038
Authors: Nima Aghdam; Michael Carrasquilla; Edina Wang; Abigail N Pepin; Malika Danner; Marilyn Ayoob; Thomas Yung; Brian T Collins; Deepak Kumar; Simeng Suy; Sean P Collins; Jonathan W Lischalk Journal: Front Oncol Date: 2021-02-25 Impact factor: 6.244
Authors: Berend J Slotman; Mary Ann Clark; Enis Özyar; Myungsoo Kim; Jun Itami; Agnès Tallet; Jürgen Debus; Raphael Pfeffer; PierCarlo Gentile; Yukihiro Hama; Nicolaus Andratschke; Olivier Riou; Philip Camilleri; Claus Belka; Magali Quivrin; BoKyong Kim; Anders Pedersen; Mette van Overeem Felter; Young Il Kim; Jin Ho Kim; Martin Fuss; Vincenzo Valentini Journal: Radiat Oncol Date: 2022-08-22 Impact factor: 4.309